Publications, trial readouts, media coverage and events from across the group.
Butkow KJ, Jalaludeen N (co-first), Liu Y, Stuchbury-Wass J, Yang Q, Ciliberto M, Ma D, Cheriyan J, Mascolo C. Nature Communications. 2026;17 July · doi:10.1038/s41467-026-75642-0. A deep-learning system that estimates cardiac stroke volume from in-ear audio captured by ordinary earbuds — mean absolute error 5.24 ml, r = 0.94 vs clinical reference — paving the way for longitudinal, scalable, out-of-clinic cardiovascular monitoring.
Read the original paperRandomised Phase 2 evidence in Nature Medicine (2026;32:624-632) that low-dose IL-2 modulates vascular inflammation after acute coronary syndrome.
Read the original paperUniversity of Cambridge (2026): News | Page 3 University of Cambridge
Read the original storyDepartment of Medicine, University of Cambridge (20 January 2026): Cambridge researchers — including Dr Joseph Cheriyan — join a UK–Australia SHE-HEALS consortium awarded £7.4 million by the Global Cardiovascular Research Funders Forum (GCRFF) to investigate how menopause shapes long-term cardiovascular risk in women. Coronary heart disease is the leading cause of death for women worldwide, and women's risk begins to rise around menopause; SHE-HEALS aims to identify early biological and clinical changes that could enable prevention.
Read the original storyUniversity of Cambridge Research News (8 January 2026) covers the IVORY trial: Cambridge researchers show that low-dose IL-2 boosts protective regulatory T-cells in patients after acute coronary syndrome, reducing blood-vessel inflammation and potentially the risk of future heart attacks.
Read the original storyGlobal Phase 3 RCT demonstrating aldosterone-synthase inhibition for uncontrolled hypertension. JAMA. 2025;334(5):409–418.
Early-career researchers from the group presented late-breaking clinical trial results at the European Society of Cardiology and American College of Cardiology congresses.
University of Cambridge (2025): Cardiovascular and Respiratory Medicine (CaRM) PIs University of Cambridge
Read the original storyUniversity of Cambridge Research News (2 September 2024) covering the first presentation of IVORY trial data at the European Society of Cardiology (ESC) Congress: low-dose IL-2 modulates vascular inflammation after acute coronary syndrome, potentially reducing the risk of future heart attacks.
Read the original storyCambridge University Hospitals (2024): Team praised for "game-changing" heart trial.
Read the original storyCambridge University Hospitals (2024): Global spotlight on Cambridge heart trial.
Read the original storyRandomised parallel-arm open-label Phase 4 trial in severe COVID-19 delivered across UK sites during the pandemic.
Nature communications. 2023;14(1):2071 · doi:10.1038/s41467-023-37424-w
Read the original paperThe inaugural clinical readout of LILACS/IVORY, published in the launch year of NEJM Evidence.
Journal of the American College of Cardiology. 2021;78(11):1127-1142 · doi:10.1016/j.jacc.2021.07.018
Read the original paperCambridge University Hospitals (22 Jun 2020): The newly launched trial, known as TACTIC-E, has been designed to test drugs specifically developed to treat Covid-19 as well as investigating whether combinations of drugs already in use can be effective.
Read the original storyKupferschmidt K. Science. 2020;368(6496):1166-1167 · doi:10.1126/science.368.6496.1166. Science magazine's June 2020 feature on the unravelling case for hydroxychloroquine, referencing the Cambridge-led PROLIFIC trial (Cheriyan et al.), paused by the UK MHRA amid emerging safety and efficacy concerns.
Read the original storyCambridge University Hospitals (22 May 2020): Until a safe and effective vaccine is available to prevent SARS-CoV-2 infection, NHS and other frontline healthcare staff will continue to remain vulnerable. Chemoprophylaxis may be an effective strategy for reducing infection in NHS staff until a successful vaccine can be produced.
Read the original storyUniversity of Cambridge Research News (10 June 2014): a daily supplement of lycopene, the natural pigment found in tomatoes, may improve blood-vessel function in patients with cardiovascular disease.
Read the original storyCirculation. 2012;126(21):2473-80 · doi:10.1161/circulationaha.112.120410
Read the original paperJACC Cardiovascular Imaging. 2012;5(9):911-22 · doi:10.1016/j.jcmg.2012.02.016
Read the original paperCirculation. 2011;123(5):515-23 · doi:10.1161/circulationaha.110.971986
Read the original paper